← brief for 2026-09-16 · Slowing decline

eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes.

Article No results yet Peer reviewed

Key takeaways

This review is about people with type 2 diabetes whose kidney disease leaks protein into the urine. It explains how doctors can safely add an SGLT2 inhibitor and finerenone on top of standard blood pressure medicine. Doctors use kidney filtering rate (eGFR) and blood potassium levels to decide when to start, adjust, or pause these drugs. It discusses a recent trial that combined the two drugs, but it reports no new results of its own.

Who did this work

Su C · Li X · Wang S · Liu D

Source

Article · PubMed, the drug frontier · 2026 Sep 10
https://pubmed.ncbi.nlm.nih.gov/42741732/